TradeOrgs
  • 🇮🇳 India
  • 🇺🇸 US
  • Screener
  • Backtest
  • Watchlist
  • Signals
  • Portfolio
  • Insights
  • Connect
Sign in
RELIANCE₹1,377.50▲ 14.60%TCS₹2,376.20▼ 3.44%HDFCBANK₹846.00▲ 18.82%ICICIBANK₹1,640.00▲ 18.75%INFY₹1,098.00▼ 2.89%HINDUNILVR₹2,052.50▲ 10.75%ITC₹299.10▲ 14.69%SBIN₹1,165.10▲ 19.66%BHARTIARTL₹2,161.70▲ 15.28%KOTAKBANK₹515.80▲ 16.62%LT₹4,209.10▲ 14.94%AXISBANK₹1,446.00▲ 16.99%ASIANPAINT₹2,608.30▲ 11.91%MARUTI₹14,011.00▲ 22.10%AAPL$342.56▲ 0.90%MSFT$484.52▼ 8.90%GOOGL$265.29▼ 22.04%AMZN$246.82▼ 6.02%NVDA$125.53▼ 42.01%META$560.84▼ 19.22%TSLA$345.82▼ 7.46%BRK-B$570.00▲ 5.59%JPM$310.53▼ 7.38%V$401.87▼ 1.16%
RELIANCE₹1,377.50▲ 14.60%TCS₹2,376.20▼ 3.44%HDFCBANK₹846.00▲ 18.82%ICICIBANK₹1,640.00▲ 18.75%INFY₹1,098.00▼ 2.89%HINDUNILVR₹2,052.50▲ 10.75%ITC₹299.10▲ 14.69%SBIN₹1,165.10▲ 19.66%BHARTIARTL₹2,161.70▲ 15.28%KOTAKBANK₹515.80▲ 16.62%LT₹4,209.10▲ 14.94%AXISBANK₹1,446.00▲ 16.99%ASIANPAINT₹2,608.30▲ 11.91%MARUTI₹14,011.00▲ 22.10%AAPL$342.56▲ 0.90%MSFT$484.52▼ 8.90%GOOGL$265.29▼ 22.04%AMZN$246.82▼ 6.02%NVDA$125.53▼ 42.01%META$560.84▼ 19.22%TSLA$345.82▼ 7.46%BRK-B$570.00▲ 5.59%JPM$310.53▼ 7.38%V$401.87▼ 1.16%

TradeOrgs shows market information and analyzes your own trading history. It does not place trades and is not investment advice.

Prices and listings are for information only. We are read-only against your broker account.

Technical signals (RSI, MACD, etc.) are educational readouts of public indicators — not recommendations.

Privacy Policy·© 2026 TradeOrgs

← US stocks

🇺🇸ALKS

Alkermes plc - Ordinary Shares

NASDAQ
$44.94
▲ $0.83 (+1.9%)
Live· just now
delayed feed · not for order timing

Price history · 20-day (cyan) / 50-day (purple) avg

as of 20 Nov 2026
H $55.67L $36.25+19.9%
$55.67$51.79$47.9$44.02$40.13$36.25$44.94
RSI (14)
Intraday · 15-minSell-20RSI 26DowntrendMACD Bearishfor day-trading context — not advice

Technical signal

Buy+35
RSI (14)49
oversold 30overbought 70
Trend
Uptrend
MACD
Bearish
Bollinger
Within bands
vs 20-day
below
vs 50-day
above
vs 200-day
above
Support
$43.45
Resistance
$48.30
  • Price is above its 50-day average (medium-term uptrend).
  • Price is above its 200-day average (long-term uptrend).

Signal backtest · 2026-02-20 → 2026-11-20

Strategy return
+35.0%
Buy & hold
+40.8%
Trades
6
Win rate
50%

$100,000.00 invested would be worth $135,029.61 (+35.0%) · Full backtester →

Hypothetical: go long when the signal turns Buy, exit when it turns Sell. Past indicator behavior is not a prediction — educational only, not advice.

About Alkermes plc· Drug Manufacturers - Specialty & Generic

source: yahoo

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
2,050
Headquarters
Dublin, Ireland
www.alkermes.com ↗

Fundamentals

No fundamental data is currently available for this listing from our data providers.

Recent news

News sentiment:▲ Positive4↑ · 1↓ · 3–
  • Rhythm Stock Is Up 32%. Is One Drug Enough?— Neutral
    Trefis · 18 Nov 2026
  • Alkermes CEO Flags Six Clinical Readouts in 12 Months, LUMRYZ Filing Ahead— Neutral
    MarketBeat · 16 Nov 2026
  • Alkermes Exclusivity Extension for Lybalvi Offsets Alixorexton Pricing Adjustment, RBC Says— Neutral
    MT Newswires · 13 Nov 2026
  • Alkermes Showcases Research From Psychiatry and Sleep Portfolios at the Neuroscience Education Institute Fall Congress

Educational technical indicators — not investment advice. TradeOrgs does not place trades.

▼ Negative
Business Wire · 05 Nov 2026
  • Alkermes' Commercial Business Appears Strong Enough to Fund Orexin Pipeline, RBC Capital Markets Says▲ Positive
    MT Newswires · 04 Nov 2026
  • RBC Raises Price Target on Alkermes Public to $57 From $56, Keeps Outperform Rating▲ Positive
    MT Newswires · 04 Nov 2026
  • Sentiment is a keyword-based read of the headline — a rough signal, not advice.